We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition

By LabMedica International staff writers
Posted on 08 Feb 2017
Image: The DRG:HYBRiD-XL random access analyzer (Photo courtesy of DRG).
Image: The DRG:HYBRiD-XL random access analyzer (Photo courtesy of DRG).
The DRG Group, a leading medical diagnostic and laboratory equipment supplier, demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

The DRG:HYBRiD-XL is a fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

DRG also highlighted its newest ELISAs such as Salivary Progesterone HS (High Sensitivity) ELISA, DHT-optimized and Hepcidin 25 (bioactive) HS ELISA kit at MEDLAB 2017. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics. DRG’s new Salivary Progesterone HS ELISA is calibrated against mass spectrometry, which is considered as gold standard in saliva diagnostics.

Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The nanotechnology-based liquid biopsy test could identify cancer at its early stages (Photo courtesy of 123RF)

2-Hour Cancer Blood Test to Transform Tumor Detection

Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more